Lecozotan

Lecozotan is a drug that was under development by Pfizer for the treatment of Alzheimer's disease. It acts as a serotonin 1A receptor antagonist and has been shown to enhance the release of acetylcholine in the brain, which is believed to improve cognitive function. However, development of the drug was discontinued in 2008 due to lack of efficacy in clinical trials.

History

Pfizer began development of Lecozotan in the early 2000s as a potential treatment for Alzheimer's disease. The drug was designed to act as a serotonin 1A receptor antagonist, which was believed to enhance the release of acetylcholine in the brain and improve cognitive function. However, in 2008, Pfizer announced that it was discontinuing development of the drug due to lack of efficacy in clinical trials.

Mechanism of Action

Lecozotan works by blocking the serotonin 1A receptor, which is believed to enhance the release of acetylcholine in the brain. Acetylcholine is a neurotransmitter that is involved in many functions in the brain, including memory and learning. By increasing the release of acetylcholine, Lecozotan was believed to improve cognitive function in patients with Alzheimer's disease.

Clinical Trials

Several clinical trials were conducted to test the efficacy of Lecozotan in treating Alzheimer's disease. However, the results of these trials were disappointing, and Pfizer decided to discontinue development of the drug in 2008.

See Also

• Pfizer
• Alzheimer's disease
• Serotonin
• Acetylcholine

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia